drugset / Trial / NCT02439450
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will test whether vaccination with viagenpumatucel-L combined with strategies to modulate the immune response is safe for patients with non-small cell lung adenocarcinoma or squamous cell carcinoma for incurable or metastatic disease.
Timeline
- Start
- 2015-04-15
- Primary completion
- 2021-05-03
- Completion
- 2022-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Viagenpumatucel-L | Vaccine | 1e+07 cells | Other |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |